Colin Clive Dalton

Vectura Group Ltd. engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium.

British Sugar Plc manufactures and distributes sugar. The company supplies cereals, confectionary, drinks, ice-cream & other dairy products, pharmaceutical & nutraceutical products, condiments, sauces, and canned goods. It was founded in 1936 and is headquartered in Peterborough, UK.

Part of Perrigo Co. Plc, Quadrant Healthcare Plc is a British company that researches, develops, and formulates drugs. The company is based in Cambridge, UK. Quadrant Healthcare was acquired by Elan Europe Ltd. on January 11, 2001 for $69.60 million.

Innovata Ltd. researches and develops pharmaceutical and medical products. It develops pulmonary products for the treatment of respiratory disorders and other serious diseases. The company was founded on July 20,1987 and is headquartered in Nottingham, the United Kingdom.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Part of Novartis AG, Coalesce Product Development Ltd. is a British company that develops inhalation devices. The company is based in Cambridge, UK. The company was founded in 2009 by Dave Ahern, who has been the CEO since 2009. Coalesce Product Development was acquired by Sandoz AG on March 14, 2022.